Business Context and Reporting Period
This Form 8-K Current Report was filed by Axsome Therapeutics, Inc. on July 13, 2016. The filing serves as a Regulation FD disclosure regarding a corporate presentation scheduled for the same date at the Cantor Fitzgerald 2nd Annual Healthcare Conference.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a disclosure of a presentation event rather than a financial results report.
Material Changes and Outlook
Management Commentary and Events:
- Herriot Tabuteau, M.D., Chief Executive Officer, is scheduled to present an overview of the Company's business.
- The presentation will focus on late-stage clinical product candidates AXS-02 and AXS-05.
- Materials for the presentation are attached as Exhibit 99.1.
Legal Status of Information:
In accordance with General Instructions B.2 and B.6 of Form 8-K, the information in Item 7.01 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the clinical status and data for product candidates AXS-02 and AXS-05 in the attached Exhibit 99.1.
- Review the full text of the presentation materials to understand the specific business overview provided by the CEO.
- Check subsequent filings for any financial updates or clinical trial results referenced in the presentation.